Supplementary Materials

Supplementary Material for:

Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo

Sriram Venneti,* Mark P. Dunphy, Hanwen Zhang, Kenneth L. Pitter, Patrick Zanzonico, Carl Campos, Sean D. Carlin, Gaspare La Rocca, Serge Lyashchenko, Karl Ploessl, Daniel Rohle, Antonio M. Omuro, Justin R. Cross, Cameron W. Brennan, Wolfgang A. Weber, Eric C. Holland, Ingo K. Mellinghoff, Hank F. Kung, Jason S. Lewis,* Craig B. Thompson*

*Corresponding author. E-mail: svenneti{at} (S.V.); thompsonc{at} (C.B.T.); lewisj2{at} (J.S.L.)

Published 11 February 2015, Sci. Transl. Med. 7, 274ra17 (2015)
DOI: 10.1126/scitranslmed.aaa1009

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Glutamine is a major TCA cycle substrate and generates 2-HG.
  • Fig. S2. 19F-FGln is not metabolized in gliomas.
  • Fig. S3. 18F-FGln shows minimal, but specific, uptake in the normal brain.
  • Fig. S4. Mouse glioma models mimic human gliomas.
  • Fig. S5. Fasting and perfusion do not affect 18F-FGln uptake.
  • Fig. S6. 18F-FGln shows uptake in mouse glioma xenografts.
  • Fig. S7. Gln is metabolized to 2-HG without altering 18F-FGln uptake.
  • Fig. S8. Glioma animal models show 18F-FGln tumor uptake.
  • Fig. S9. Neuroinflammatory mouse models do not show 18F-FGln uptake.
  • Fig. S10. Chemoradiation decreases tumor burden and improves survival.
  • Fig. S11. Chemoradiation therapy results in increased gliosis.
  • Fig. S12. SLC1A5 partly mediates 18F-FGln uptake and is expressed in human gliomas.
  • Fig. S13. Patients imaged with 18F-FGln show glioma SLC1A5 expression.
  • Fig. S14. 18F-FGln shows uptake in a clinically progressive glioma.
  • Fig. S15. 18F-FGln does not show uptake in a clinically stable glioma.
  • Fig. S16. 18F-FGln shows clearance from blood and plasma.
  • Table S1. Patient characteristics.
  • Table S2. Comparison of 18F-FGln and 18F-FDG imaging in human subjects.
  • Table S3. Biodistribution of 18F-FGln in human subjects.
  • Table S4.18F-FGln parent compound and radiometabolites in plasma at 1, 30, and 60 min after tracer injection.
  • Table S5. 18F-FGln dosimetry in human subjects.
  • References (29, 30)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S6. P values (provided as a separate Excel file).
  • Table S7. Data used to generate graphs (provided as a separate Excel file).

[Download Tables S6 and S7]